Imperial Capital’s Michael Derchin and Adam Hackel contend that American Airlines’ (AAL) “strong management skills [will] be tested once again.” They explain why:
We are initiating coverage ofAmerican Airlines shares with an In-Line rating and a one-year price target of $40, about 9% above the recent share price. One of the most under-appreciated management achievements in recent years, in our view, was AAL’s ability to report record net profit and pretax margins while flawlessly executing the Herculean integration of AMR and US Airways. Added to the challenges were two major headwinds: 1) the disintegration of its most profitable geographic region, Latin America, as Venezuela and Brazil economies imploded, and 2) the sunset of the Wright Amendment, which unleashed the low fares of Southwest Airlines (LUV), which in turn undermined the profitability of AAL’s very profitable Dallas/Fort Worth hub.
stock top picks: Catabasis Pharmaceuticals, Inc.(CATB)
- [By Lisa Levin]
Shares of Catabasis Pharmaceuticals Inc (NASDAQ: CATB) got a boost, shooting up 46 percent to $6.52. Catabasis Pharmaceuticals and Sarepta Therapeutics Inc (NASDAQ: SRPT) reported a joint research collaboration in Duchenne Muscular Dystrophy.
stock top picks: Genesis Energy, L.P.(GEL)
- [By Lisa Levin]
Lennar Corporation (NYSE: LEN) reported better-than-expected profit for its first quarter on Tuesday.
General Mills, Inc. (NYSE: GIS) reported upbeat earnings for its fiscal third quarter, while sales missed estimates.
Genesis Energy, L.P. (NYSE: GEL) disclosed that it has priced its public offering of 4 million common units for gross proceeds of $124 million.
South State Corporation (NASDAQ: SSB) reported that it has increased its buyback plan from 250,000 shares to 1 million shares.
stock top picks: StoneMor Partners L.P.(STON)
- [By Monica Gerson]
The list of below stocks is notable as the shares have traded on sequentially increasing volume spanning the trading days from September 16 to September 20:
stock top picks: ImmunoCellular Therapeutics, Ltd.(IMUC)
- [By Paul Ausick]
ImmunoCellular Therapeutics Ltd. (NYSEMKT: IMUC) posted a new 52-week low of $0.48 on Tuesday, down nearly 61% compared with Monday’s closing price of $1.22. Volume totaled around 7.3 million shares, nearly 25 times the daily average. The company had no specific news Tuesday. The company price an offering of 5,000 preferred stock and warrants to purchase another 9,000 shares of preferred stock a $1,000 per share to raise approximately $5 million.
stock top picks: VIVUS, Inc.(VVUS)
- [By Keith Speights]
Arena is out of the obesity drug business, but what about Orexigen Therapeutics (NASDAQ:OREX) or VIVUS (NASDAQ:VVUS)? The problem is that they’re both too dependent on their respective obesity drugs, Contrave and Qsymia. Neither of the drugs have performed up to expectations.
- [By Peter Graham]
A long term chart shows Arena Pharmaceuticals along with its small capobesitytreatmentpeers EnteroMedics Inc (NASDAQ: ETRM), Orexigen Therapeutics, Inc (NASDAQ: OREX) and VIVUS, Inc (NASDAQ: VVUS) all causing severe weight loss for investor portfolios: